Strategy expanded its ability to raise capital via at‑the‑market equity and preferred offerings, adding new agents and adjusting stock authorization, allowing up to $44.1 billion in additional ...

Strategy announced new capital-raising programs to support more Bitcoin purchases. The company filed details in a Form 8-K with the U.S. Securities and Exchange Commission. The update affirmed new ...

Lithium Americas (LAC) is spending $1.3B to $1.6B on 2026 capital expenditures at its Thacker Pass project with a $2.23B DOE loan facility and 38% General Motors joint venture backing the development.

Malibu, CA, March 18, 2026 (GLOBE NEWSWIRE) -- Trio Petroleum Corp (TPET) (NYSE American: “TPET”, “Trio” or the “Company”), an oil and gas company, announced that as of March 18, 2026, the Company had ...

Strategy (MSTR) stock is up 5% today as Bitcoin’s (BTC) 6% weekly gain fuels fresh optimism around Strategy’s record-breaking Bitcoin treasury. Strategy now holds around 761,000 BTC valued at ...

Mon, March 16, 2026 at 6:12 PM UTC The context matters here. MSTR was down about 8% year-to-date heading into today, so this pop represents a meaningful reversal off recent lows. The stock's 52-week ...

IREN Limited is aggressively expanding AI cloud capacity, targeting 150,000 GPUs and $3.7 billion annualized run-rate revenue by 2026. IREN's vertically integrated model offers operational flexibility ...

As part of efforts to boost access to cash, the Central Bank of Nigeria (CBN) has mandated that all banks and card issuers must deploy at least one Automated Teller Machine (ATM) for every 7,500 ...

Marathon Digital (MARA) stock spiked 7% amid a Bitcoin price surge, demonstrating the stock’s extreme sensitivity wherein a $10,000 Bitcoin swing drives roughly $530 million in earnings swings. MPLX ...

CEO Travers described a "wave of OEM business" as a visible inflection, stating production contracts and engineering partnerships with large brands and the defense sector are already underway or ...

Phase 3 trial of once-weekly canvuparatide remains on track to initiate in Q3 2026 following recently completed, successful End-of-Phase 2 meeting with FDA 12-week MAD Phase 1 data from MBX 4291 for ...